Eimear E Kenny | Mount Sinai

Biography

Research Topics

Genetics, Genomics

Multi-Disciplinary Training Area

Disease Mechanisms and Therapeutics (DMT), Neuroscience [NEU]

Education

BSc, Trinity College Dublin

MSc, University of Leeds

PhD, Rockefeller University

Post-doc, Stanford University

Publications

210

Publications

Selected Publications

Rare damaging CCR2 variants are associated with lower lifetime cardiovascular risk. Marios K. Georgakis, Rainer Malik, Omar El Bounkari, Natalie R. Hasbani, Jiang Li, Jennifer E. Huffman, Gabrielle Shakt, Reinier W.P. Tack, Tamara N. Kimball, Yaw Asare, Alanna C. Morrison, Noah L. Tsao, Renae Judy, Braxton D. Mitchell, Huichun Xu, May E. Montasser, Ron Do, Eimear E. Kenny, Ruth J.F. Loos, James G. Terry, John Jeffrey Carr, Joshua C. Bis, Bruce M. Psaty, W. T. Longstreth, Kendra A. Young, Sharon M. Lutz, Michael H. Cho, Jai Broome, Alyna T. Khan, Fei Fei Wang, Nancy Heard-Costa, Sudha Seshadri, Ramachandran S. Vasan, Nicholette D. Palmer, Barry I. Freedman, Donald W. Bowden, Lisa R. Yanek, Brian G. Kral, Lewis C. Becker, Patricia A. Peyser, Lawrence F. Bielak, Farah Ammous, April P. Carson, Michael E. Hall, Laura M. Raffield, Stephen S. Rich, Wendy S. Post, Russel P. Tracy, Kent D. Taylor, Xiuqing Guo, Michael C. Mahaney, Joanne E. Curran, John Blangero, Shoa L. Clarke, Jeffrey W. Haessler, Yao Hu, Themistocles L. Assimes, Charles Kooperberg, Jürgen Bernhagen, Christopher D. Anderson, Scott M. Damrauer, Ramin Zand, Jerome I. Rotter, Paul S. de Vries, Martin Dichgans. Genome Medicine

Evolving knowledge of red flag clinical features associated with TTR p.(Val142Ile) in a diverse electronic health-record-linked biobank. Amy R. Kontorovich, Connor B. Benson, Alexandra McClellan, Gillian M. Belbin, Eimear E. Kenny, Noura S. Abul-Husn. Genetics in Medicine

Sequencing in over 50,000 cases identifies coding and structural variation underlying atrial fibrillation risk. Seung Hoan Choi, Sean J. Jurgens, Ling Xiao, Matthew C. Hill, Christopher M. Haggerty, Garðar Sveinbjörnsson, Valerie N. Morrill, Nicholas A. Marston, Lu Chen Weng, James P. Pirruccello, David O. Arnar, Daniel Fannar Gudbjartsson, Helene Mantineo, Aenne S. von Falkenhausen, Andrea Natale, Arnljot Tveit, Bastiaan Geelhoed, Carolina Roselli, David R. Van Wagoner, Dawood Darbar, Doreen Haase, Elsayed Z. Soliman, Giovanni E. Davogustto, Goo Jun, Hugh Calkins, Jeffrey L. Anderson, Jennifer A. Brody, Jennifer L. Halford, John Barnard, John E. Hokanson, Jonathan D. Smith, Joshua C. Bis, Kendra Young, Linda S.B. Johnson, Lorenz Risch, Lorne J. Gula, Lydia Coulter Kwee, Mark D. Chaffin, Michael Kühne, Michael Preuss, Namrata Gupta, Navid A. Nafissi, Nicholas L. Smith, Peter M. Nilsson, Pim van der Harst, Quinn S. Wells, Roelof A.J. Smit, Girish Nadkarni, Eimear Kenny, Bruce Gelb. Nature Genetics

View All Publications

Video

Population Genomic Health: Bridging Genomics into Clinical Care

Office Locations

Annenberg Building Floor 18 Room 18

1468 Madison Ave

New York, NY 10029

212-241-3878

Annenberg Building Floor 18 Room 18

1468 Madison Ave

New York, NY 10029

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Kenny during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Board Service

Overtone
Galateo Bio

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

Galateo Bio

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Kenny during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Board Service

Overtone
Galateo Bio

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

Galateo Bio

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.